目的 研究前列癃闭通片联合爱普列特治疗良性前列腺增生症的临床疗效。方法 选择2023年2月—2024年6月苏州大学附属第四医院收治的良性前列腺增生症患者152例，随机分为对照组（74例）和治疗组（78例）。对照组口服爱普列特片，5 mg/次，2次/d。治疗组在对照组基础上口服前列癃闭通片，3片/次，3次/d。两组患者连续治疗4个月。观察两组患者临床疗效，比较治疗前后两组患者国际前列腺症状评分（IPSS）评分，最大尿流率和减少残余尿量，血清性激素睾酮（T）和雌二醇（E₂）水平，及血清炎症因子C反应蛋白（CRP）、白细胞介素-6（IL-6）和肿瘤坏死因子α（TNF-α）水平。结果 治疗后，治疗组临床总有效率明显高于对照组（97.43% vs 83.78%，P＜0.05）。治疗后，与治疗前相比，两组IPSS评分明显下降（P＜0.05），且治疗组患者IPSS评分明显低于对照组（P＜0.05）。治疗后，两组的最大尿流率均显著提高，残余尿量显著减少（P＜0.05），且治疗组尿动力学参数明显优于对照组（P＜0.05）。治疗后，两组T水平明显升高，而E₂水平明显下降（P＜0.05），且治疗组性激素水平明显好于对照组（P＜0.05）。治疗后，两组血清CRP、IL-6、TNF-α水平与治疗前相比明显下降，且治疗组上述3种炎症因子水平和对照组相比明显降低（P＜0.05）。结论 前列癃闭通片联合爱普列特治疗良性前列腺增生症具有良好的临床疗效，能有效改善性激素水平、尿动力学指标和血清炎症因子，且治疗效果优于单一药物治疗。

Objective To study the clinical efficacy of Qianlielong Bitong Tablets combined with aipulite in treatment of benign prostatic hyperplasia. Methods Patients (152 cases) with benign prostatic hyperplasia in the Fourth Affiliated Hospital of Soochow University from February 2023 to June 2024 were randomly divided into control (74 cases) and treatment (78 cases) group. Patient in the control group were po administered with Epristeride Tablets, 5 mg/time, twice daily. Patient in the treatment group were po administered with Qianlielong Bitong Tablets on the basis of the control group, 3 tablets/time, three times daily. Patient in two groups were treated for 4 months. After treatment, the clinical evaluations were evaluated, and the IPSS scores, the maximum urinary flow rate and residual urine volume in bladder, sex hormone T and E₂ levels, and serum factors CRP, IL-6, TNF-α levels in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was significantly higher than that in the control group (97.43% vs 83.78%, P < 0.05). After treatment, compared with before treatment, the IPSS scores in two groups were decreased significantly (P < 0.05), and the IPSS scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the maximum urinary flow rate in two groups was significantly increased, residual urine volume was significantly reduced (P < 0.05), and the urodynamic parameters of the treatment group were significantly better than those of the control group (P < 0.05). After treatment, T levels were significantly increased in two groups, but E₂ levels were significantly decreased (P < 0.05), and sex hormone levels in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the levels of serum CRP, IL-6, and TNF-α in two groups were decreased significantly compared with before treatment, and the levels of the above three inflammatory factors in the treatment group were significantly decreased compared with the control group (P < 0.05). Conclusion The combined treatment of Qianlielong Bitong Tablets and epristeride for benign prostatic hyperplasia demonstrates has good clinical efficacy. It effectively improves sex hormone levels, urodynamic parameters, and serum inflammatory factors, and the treatment effect is superior to monotherapy.

R983

江苏省卫生健康委科研课题（ZD2023042）